Medication evidence profile
Rupatadine
Clinical overview
Rupatadine has public medication-list entries in JARS 2025 and Yamada-ABS 2023. These are 2 separate source versions, each with its own evidence and definitions.
Source-specific scores
| Source | Score |
|---|---|
| JARS | 1 |
| Yamada-ABS | 2 |
| BAAS | Not listed |
| Swe-ABS | Not listed |
| GABS | Not listed |
| KABS | Not listed |
| CALS | Not listed |
How to read this: 0 means the source explicitly assigned zero. “Not listed” means the source did not provide a score for this medication. Scores from different scales are not averaged.
How to interpret the evidence
2 of 7 public source versions contain an explicit medication-list entry for Rupatadine.
The recorded values differ across the source rows for Rupatadine. Scale methods, definitions, source eras, evidence types and identity handling can differ; the numbers alone do not establish the reason for this medication’s disagreement.
None of the public rows in this profile is an explicit zero. An unlisted source still supplies no value.
Source labels and provenance · 2 observations
- Japanese Anticholinergic Risk Scale (JARS) 2025 English translation
Source label: Rupatadine. Published value: 1.
Source version: JARS-2025
Source location: RC4 source recovery; recovery_scope=primary_table_complete; ATC=R06AX28
Observation: JARS_2025_R0146; rating state: published_rating. - Yamada Pharmacological Anticholinergic Burden Scale 2023
Source label: Rupatadine. Published value: 2.
Source version: YAMADA-ABS-2023
Source location: RC4 source recovery; recovery_scope=primary_nonzero_complete
Observation: YAMADA_ABS_2023_R0043; rating state: published_rating.
Dose, route, and formulation notes
Distinct v3 concept retained conservatively; do not collapse by substring or class similarity.
What this page does not establish
- No medication-list entry is available here from BAAS 2019, Swe-ABS 2023, GABS 2018, KABS 2020 open validation supplement, and CALS 2022 Table 4. These gaps remain “Not listed”; no score is inferred from another source or from class membership.
- Use source-specific route/formulation where provided.
- These source records do not estimate an individual’s probability of harm or establish whether to start, stop or change a medication. Ordinal source scores are not averaged into a UnifiedACB score.
References
- Mizokami F, Mizuno T, Taguchi R, et al. Development of the Japanese Anticholinergic Risk Scale: English translation of the Japanese article. Geriatr Gerontol Int. 2025;25(1):5-13. doi:10.1111/ggi.15001. Open source
- Yamada S, Mochizuki M, Chimoto J, Futokoro R, Kagota S, Shinozuka K. Development of a pharmacological evidence-based anticholinergic burden scale for medications commonly used in older adults. Geriatr Gerontol Int. 2023;23(7):558-564. doi:10.1111/ggi.14619. Open source
Ask a follow-up
Go to your medication comparison · How UnifiedACB handles disagreement
Ask about this medication
Medication context: Rupatadine
Ask about this medication